Aridis Pharmaceuticals (ARDS) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends ARDS vs. SCPS, NAVB, EVLO, CMRA, GNCAQ, GNCA, STAB, AMPE, CALA, and EFTRShould you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Scopus BioPharma (SCPS), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Calithera Biosciences (CALA), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Aridis Pharmaceuticals vs. Scopus BioPharma Navidea Biopharmaceuticals Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Statera Biopharma Ampio Pharmaceuticals Calithera Biosciences eFFECTOR Therapeutics Scopus BioPharma (NASDAQ:SCPS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking. Do insiders and institutionals have more ownership in SCPS or ARDS? 9.7% of Aridis Pharmaceuticals shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in SCPS or ARDS? Aridis Pharmaceuticals received 120 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 61.00% of users gave Aridis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo VotesAridis PharmaceuticalsOutperform Votes12261.00% Underperform Votes7839.00% Is SCPS or ARDS more profitable? Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Aridis Pharmaceuticals N/A N/A N/A Does the media prefer SCPS or ARDS? In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score. Company Overall Sentiment Scopus BioPharma Neutral Aridis Pharmaceuticals Neutral Which has more risk and volatility, SCPS or ARDS? Scopus BioPharma has a beta of -0.21, indicating that its share price is 121% less volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Which has stronger valuation and earnings, SCPS or ARDS? Scopus BioPharma has higher earnings, but lower revenue than Aridis Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/AAridis Pharmaceuticals$3.09M0.00-$30.37MN/AN/A SummaryAridis Pharmaceuticals beats Scopus BioPharma on 5 of the 7 factors compared between the two stocks. Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDS vs. The Competition Export to ExcelMetricAridis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$6.58B$5.40B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A10.0188.8317.53Price / SalesN/A335.371,284.8780.52Price / CashN/A22.6336.6032.90Price / BookN/A5.084.964.69Net Income-$30.37M$154.90M$117.89M$224.57M Aridis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDSAridis PharmaceuticalsN/AN/AN/AN/A$0.00$3.09M0.0030SCPSScopus BioPharmaN/A$0.00flatN/A-91.4%$13,000.00N/A0.009High Trading VolumeNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-99.8%$10,000.00$8,126.000.0010Analyst ForecastNews CoverageEVLOEvelo BiosciencesN/A$0.00flatN/A-99.1%$9,000.00N/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6,000.00$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.64M0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastSTABStatera BiopharmaN/A$0.00flatN/A-83.3%$5,000.00$1.49M0.0020AMPEAmpio PharmaceuticalsN/A$0.00-97.0%N/A-99.8%$3,000.00N/A0.0020Analyst ForecastNews CoverageGap DownCALACalithera BiosciencesN/A$0.00flatN/A-99.4%$1,000.00$9.75M0.0060Analyst ForecastNews CoverageEFTReFFECTOR Therapeutics1.2474 of 5 stars$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010High Trading Volume Related Companies and Tools Related Companies SCPS Alternatives NAVB Alternatives EVLO Alternatives CMRA Alternatives GNCAQ Alternatives GNCA Alternatives STAB Alternatives AMPE Alternatives CALA Alternatives EFTR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARDS) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARDS Stock Alerts